Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-Current Assets: 2018-2025

Historic Non-Current Assets for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $2.0 million.

  • Whitehawk Therapeutics' Non-Current Assets fell 76.37% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 76.37%. This contributed to the annual value of $9.0 million for FY2024, which is 15.25% up from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Non-Current Assets of $2.0 million as of Q3 2025, which was down 7.90% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Non-Current Assets registered a high of $9.0 million during Q4 2024, and its lowest value of $29,452 during Q2 2021.
  • Over the past 3 years, Whitehawk Therapeutics' median Non-Current Assets value was $6.8 million (recorded in 2023), while the average stood at $6.1 million.
  • In the last 5 years, Whitehawk Therapeutics' Non-Current Assets crashed by 89.52% in 2021 and then soared by 14,503.42% in 2022.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Non-Current Assets stood at $6.6 million in 2021, then tumbled by 36.61% to $4.2 million in 2022, then skyrocketed by 86.24% to $7.8 million in 2023, then rose by 15.25% to $9.0 million in 2024, then crashed by 76.37% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.2 million for Q2 2025, and $1.4 million during Q1 2025.